EPS: As of FY2025 Q2, the actual value is USD -2.27.

Segment Revenue

• Revenue: The company reported no revenue for the three and six months ended October 31, 2024, compared to $4,000 for the same periods in 2023.

Operational Metrics

• Net Loss: The net loss for the three months ended October 31, 2024, was $2.1 million, an increase from $1.7 million in the same period in 2023. For the six months ended October 31, 2024, the net loss was $4.1 million, compared to $3.1 million in 2023.
• Research and Development Expenses: R&D expenses were $1.2 million for the three months ended October 31, 2024, up from $757,000 in 2023, and $2.4 million for the six months ended October 31, 2024, up from $1.3 million in 2023.
• Selling, General and Administrative Expenses: These expenses were $786,000 for the three months ended October 31, 2024, a slight decrease from $815,000 in 2023, and $1.6 million for the six months ended October 31, 2024, up from $1.6 million in 2023.

Cash Flow

• Net Cash Used in Operating Activities: The company used $4.2 million in operating activities for the six months ended October 31, 2024, compared to $2.4 million in 2023.
• Net Cash Provided by Financing Activities: The company generated $2.5 million from financing activities for the six months ended October 31, 2024, compared to $839,000 in 2023.

Future Outlook and Strategy

• Core Business Focus: The company plans to submit the MyoVista wavECG device for FDA clearance under the 510(k) pathway in the first calendar quarter of 2025, aiming to market and sell the device in the U.S. upon successful clearance.
• Non-Core Business: The company is developing the MyoVista Insights Cloud Platform to host AI-ECG algorithms and plans to submit it for FDA clearance in the second half of 2025.